Company
(Location)

Product

Description

Indication

Status

Date


Chimerix Inc. (Durham, N.C.)

CMX001

Brincidofovir; oral nucleotide analog lipid-conjugate

Hematopoietic cell transplant recipients with early adenovirus infection

Phase II data showed it demonstrated activity against all pathogenic families of double-stranded DNA viruses, including herpesviruses, adenoviruses and polyomaviruses

9/12/13

Durata Therapeutics Inc. (Chicago)

Dalbavancin

Second-generation, semi-synthetic lipoglycopeptide

Acute bacterial skin and skin structure infections

Phase II data showed it was non-inferior to the comparator regimen, vancomycin with an option to switch to oral linezolid

9/12/13

Genocea Biosciences Inc. (Cambridge, Mass.)

GEN-003

A first-in-class protein subunit vaccine

Genital herpes

Phase I/IIa data showed that patients who received three doses had reductions in the frequency of viral shedding of up to 51%

9/16/13

Gilead Sciences Inc. (Foster City, Calif.)

TAF

Once-daily single tablet regimen containing tenofovir alafenamide

HIV-1 infection

Phase II data showed it was similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL, and was associated with more favorable renal and bone safety markers

9/16/13

Novavax Inc. (Rockville, Md.)

Vaccine

Respiratory syncytial virus F-protein nanoparticle vaccine

Respiratory syncytial virus

Phase I data showed the vaccine was compatible with co-administration of influenza vaccine; it also was well tolerated, and yielded increases in antibodies

9/12/13

Sangamo Biosciences Inc. (Richmond, Calif.)

SB-728-T

ZFP therapy

HIV/AIDS

Phase II data demonstrated functional control of the virus at or below the limit of detection in CCR5 delta-32 heterozygote HIV-infected subjects

9/16/13

Theraclone Sciences Inc. (Seattle)

TCN-202

A recombinant fully human monoclonal antibody

Cytomegalo-virus

Phase I data showed it was well tolerated, with no dose-limiting toxicities or serious adverse events, and had a favorable immunogenicity profile

9/12/13

Viiv Healthcare Inc. (London)

Tivicay

Dolutegravir

HIV

Phase IIIb/IV data demonstrated noninferiority to darunavir

9/16/13


Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

The date indicated refers to the BioWorld Today issue in which the news item can be found.